Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia

Anastasiia S. Boiko, Irina A. Mednova, Elena G. Kornetova, Arkadiy V. Semke, Nikolay A. Bokhan, Anton J.M. Loonen, Svetlana A. Ivanova

Результат исследований: Материалы для журналаСтатья

Выдержка

Background: Schizophrenia is associated with a lowered life expectancy due to cardiovascular disease. This is, at least in part, related to an increased vulnerability to the development of metabolic syndrome (MetS) in patients with schizophrenia. The dysregulation of apolipoproteins (Apos) may also play a role in the pathogenesis of schizophrenia via their effect on cerebral cholesterol processing. Aim: The aim of this study was to investigate serum Apos A1, C3, E, A2 and C2 concentration in schizophrenia patients with or without MetS in comparison to healthy donors. Methods: After obtaining informed consent, 53 patients with a diagnosis of paranoid schizophrenia according to ICD-10 criteria (F20) were included. Patients were divided into two groups with (N = 26) and without (N = 27) MetS according to the criteria of the International Diabetes Federation. The control group included 20 mentally and physically healthy subjects. Serum Apos A1, A2, C2, C3 and E were measured using xMAP technology (Luminex). Results: Serum ApoA1 was significantly decreased in patients with schizophrenia compared to healthy subjects (p = 0.002); ApoA2 was lower in patients without MetS in comparison to patients with MetS (p = 0.017) and the levels of ApoC3 and ApoC2 were increased in patients with schizophrenia with MetS in comparison with the control group and also with patients without MetS. No other significant differences were established concerning the other assayed apolipoproteins. Conclusions: In line with literature data the results of our study suggest that while disturbances in ApoA1 level may play a role in the pathogenesis of schizophrenia, ApoA2, ApoC2, ApoC3 and ApoE may be primarily related to metabolic imbalance.

Язык оригиналаАнглийский
Номер статьиe02033
ЖурналHeliyon
Том5
Номер выпуска7
DOI
СостояниеОпубликовано - 1 июл 2019

Отпечаток

Apolipoproteins
Schizophrenia
Serum
Apolipoprotein C-II
Apolipoprotein A-I
Healthy Volunteers
Apolipoprotein A-II
Paranoid Schizophrenia
Control Groups
Apolipoproteins E
International Classification of Diseases
Life Expectancy
Informed Consent
varespladib methyl
Cardiovascular Diseases
Cholesterol
Tissue Donors
Technology

ASJC Scopus subject areas

  • General

Цитировать

Boiko, A. S., Mednova, I. A., Kornetova, E. G., Semke, A. V., Bokhan, N. A., Loonen, A. J. M., & Ivanova, S. A. (2019). Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia. Heliyon, 5(7), [e02033]. https://doi.org/10.1016/j.heliyon.2019.e02033

Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia. / Boiko, Anastasiia S.; Mednova, Irina A.; Kornetova, Elena G.; Semke, Arkadiy V.; Bokhan, Nikolay A.; Loonen, Anton J.M.; Ivanova, Svetlana A.

В: Heliyon, Том 5, № 7, e02033, 01.07.2019.

Результат исследований: Материалы для журналаСтатья

Boiko, AS, Mednova, IA, Kornetova, EG, Semke, AV, Bokhan, NA, Loonen, AJM & Ivanova, SA 2019, 'Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia', Heliyon, том. 5, № 7, e02033. https://doi.org/10.1016/j.heliyon.2019.e02033
Boiko AS, Mednova IA, Kornetova EG, Semke AV, Bokhan NA, Loonen AJM и соавт. Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia. Heliyon. 2019 Июль 1;5(7). e02033. https://doi.org/10.1016/j.heliyon.2019.e02033
Boiko, Anastasiia S. ; Mednova, Irina A. ; Kornetova, Elena G. ; Semke, Arkadiy V. ; Bokhan, Nikolay A. ; Loonen, Anton J.M. ; Ivanova, Svetlana A. / Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia. В: Heliyon. 2019 ; Том 5, № 7.
@article{7ed71ca30a8447e9be85f66c40287cea,
title = "Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia",
abstract = "Background: Schizophrenia is associated with a lowered life expectancy due to cardiovascular disease. This is, at least in part, related to an increased vulnerability to the development of metabolic syndrome (MetS) in patients with schizophrenia. The dysregulation of apolipoproteins (Apos) may also play a role in the pathogenesis of schizophrenia via their effect on cerebral cholesterol processing. Aim: The aim of this study was to investigate serum Apos A1, C3, E, A2 and C2 concentration in schizophrenia patients with or without MetS in comparison to healthy donors. Methods: After obtaining informed consent, 53 patients with a diagnosis of paranoid schizophrenia according to ICD-10 criteria (F20) were included. Patients were divided into two groups with (N = 26) and without (N = 27) MetS according to the criteria of the International Diabetes Federation. The control group included 20 mentally and physically healthy subjects. Serum Apos A1, A2, C2, C3 and E were measured using xMAP technology (Luminex). Results: Serum ApoA1 was significantly decreased in patients with schizophrenia compared to healthy subjects (p = 0.002); ApoA2 was lower in patients without MetS in comparison to patients with MetS (p = 0.017) and the levels of ApoC3 and ApoC2 were increased in patients with schizophrenia with MetS in comparison with the control group and also with patients without MetS. No other significant differences were established concerning the other assayed apolipoproteins. Conclusions: In line with literature data the results of our study suggest that while disturbances in ApoA1 level may play a role in the pathogenesis of schizophrenia, ApoA2, ApoC2, ApoC3 and ApoE may be primarily related to metabolic imbalance.",
keywords = "Antipsychotic drugs, Apolipoprotein, Biomarker, Cardiology, Metabolic syndrome, Metabolism, Neuroscience, Schizophrenia",
author = "Boiko, {Anastasiia S.} and Mednova, {Irina A.} and Kornetova, {Elena G.} and Semke, {Arkadiy V.} and Bokhan, {Nikolay A.} and Loonen, {Anton J.M.} and Ivanova, {Svetlana A.}",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.heliyon.2019.e02033",
language = "English",
volume = "5",
journal = "Heliyon",
issn = "2405-8440",
publisher = "Elsevier BV",
number = "7",

}

TY - JOUR

T1 - Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia

AU - Boiko, Anastasiia S.

AU - Mednova, Irina A.

AU - Kornetova, Elena G.

AU - Semke, Arkadiy V.

AU - Bokhan, Nikolay A.

AU - Loonen, Anton J.M.

AU - Ivanova, Svetlana A.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Background: Schizophrenia is associated with a lowered life expectancy due to cardiovascular disease. This is, at least in part, related to an increased vulnerability to the development of metabolic syndrome (MetS) in patients with schizophrenia. The dysregulation of apolipoproteins (Apos) may also play a role in the pathogenesis of schizophrenia via their effect on cerebral cholesterol processing. Aim: The aim of this study was to investigate serum Apos A1, C3, E, A2 and C2 concentration in schizophrenia patients with or without MetS in comparison to healthy donors. Methods: After obtaining informed consent, 53 patients with a diagnosis of paranoid schizophrenia according to ICD-10 criteria (F20) were included. Patients were divided into two groups with (N = 26) and without (N = 27) MetS according to the criteria of the International Diabetes Federation. The control group included 20 mentally and physically healthy subjects. Serum Apos A1, A2, C2, C3 and E were measured using xMAP technology (Luminex). Results: Serum ApoA1 was significantly decreased in patients with schizophrenia compared to healthy subjects (p = 0.002); ApoA2 was lower in patients without MetS in comparison to patients with MetS (p = 0.017) and the levels of ApoC3 and ApoC2 were increased in patients with schizophrenia with MetS in comparison with the control group and also with patients without MetS. No other significant differences were established concerning the other assayed apolipoproteins. Conclusions: In line with literature data the results of our study suggest that while disturbances in ApoA1 level may play a role in the pathogenesis of schizophrenia, ApoA2, ApoC2, ApoC3 and ApoE may be primarily related to metabolic imbalance.

AB - Background: Schizophrenia is associated with a lowered life expectancy due to cardiovascular disease. This is, at least in part, related to an increased vulnerability to the development of metabolic syndrome (MetS) in patients with schizophrenia. The dysregulation of apolipoproteins (Apos) may also play a role in the pathogenesis of schizophrenia via their effect on cerebral cholesterol processing. Aim: The aim of this study was to investigate serum Apos A1, C3, E, A2 and C2 concentration in schizophrenia patients with or without MetS in comparison to healthy donors. Methods: After obtaining informed consent, 53 patients with a diagnosis of paranoid schizophrenia according to ICD-10 criteria (F20) were included. Patients were divided into two groups with (N = 26) and without (N = 27) MetS according to the criteria of the International Diabetes Federation. The control group included 20 mentally and physically healthy subjects. Serum Apos A1, A2, C2, C3 and E were measured using xMAP technology (Luminex). Results: Serum ApoA1 was significantly decreased in patients with schizophrenia compared to healthy subjects (p = 0.002); ApoA2 was lower in patients without MetS in comparison to patients with MetS (p = 0.017) and the levels of ApoC3 and ApoC2 were increased in patients with schizophrenia with MetS in comparison with the control group and also with patients without MetS. No other significant differences were established concerning the other assayed apolipoproteins. Conclusions: In line with literature data the results of our study suggest that while disturbances in ApoA1 level may play a role in the pathogenesis of schizophrenia, ApoA2, ApoC2, ApoC3 and ApoE may be primarily related to metabolic imbalance.

KW - Antipsychotic drugs

KW - Apolipoprotein

KW - Biomarker

KW - Cardiology

KW - Metabolic syndrome

KW - Metabolism

KW - Neuroscience

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85068214654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068214654&partnerID=8YFLogxK

U2 - 10.1016/j.heliyon.2019.e02033

DO - 10.1016/j.heliyon.2019.e02033

M3 - Article

VL - 5

JO - Heliyon

JF - Heliyon

SN - 2405-8440

IS - 7

M1 - e02033

ER -